Holen Sie sich die Stockscreener-App
1.08
5.26%
-0.06
Handel nachbörslich:
1.07
-0.01
-0.93%
Schlusskurs vom Vortag:
$1.14
Offen:
$1.08
24-Stunden-Volumen:
428.17K
Relative Volume:
1.55
Marktkapitalisierung:
$16.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.29M
KGV:
-1.5429
EPS:
-0.7
Netto-Cashflow:
$-6.47M
1W Leistung:
-10.74%
1M Leistung:
-10.74%
6M Leistung:
-26.53%
1J Leistung:
-21.17%
1-Tages-Spanne:
$1.00
$1.10
1-Wochen-Bereich:
$1.00
$1.23
52-Wochen-Spanne:
$1.00
$3.59
NanoViricides Inc Stock (NNVC) Company Profile
Firmenname
NanoViricides Inc
Sektor
Branche
Telefon
203-937-6137
Adresse
1 Controls Drive, Shelton, CT
Vergleichen Sie NNVC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.08 | 16.89M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2015-02-11 | Eingeleitet | Midtown Partners | Strong Buy |
NanoViricides Inc Aktie (NNVC) Neueste Nachrichten
NNVC stock touches 52-week low at $1.02 amid market challenges - Investing.com
NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate - Proactive financial news
Virtu Financial LLC Acquires New Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
Small cap wrap: NanoViricides, G Mining Ventures, Nevis Brands... - Proactive Investors
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative - Proactive Investors
NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101 - ACCESS Newswire
NanoViricides (NYSE:NNVC) Trading Up 1.7% – Time to Buy? - Defense World
Stock Update - Investorsobserver
AllPennyStocks.com News: Junior Biotech Bounces off $1; Chart Trying to Turn Bullish - ACCESS Newswire
Market movers: Delta, Kohl's, Asana, NanoViricides... - Proactive Investors UK
NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline - Proactive financial news
Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments - Marketscreener.com
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company - Jonesboro Sun
Springing into action in time of need: NanoViricides, Inc. (NNVC.OB) - ACCESS Newswire
Unicycive Therapeutics Inc (NASDAQ:UNCY) stock: Is this a flash in the pan today? - US Post News
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan - Lelezard
NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak - Proactive financial news
Investornewsbreaks Nanoviricides (NYSE American: NNVC) Highlights NV-387 As Potential Measles Treatment Amid Outbreak - MENAFN.COM
NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering - ACCESS Newswire
Mpox – a possible US$100mln+ opportunity - Proactive Investors USA
NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101 - ACCESS Newswire
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - ACCESS Newswire
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready - ACCESS Newswire
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2020Has Sufficient Cash, Progress on New Coronavirus Drug Program and the Lead HerpeCide(TM) Drug Candidate IND Application - ACCESS Newswire
NanoViricides Receives Cash Infusion of $2.25 Million - ACCESS Newswire
NanoViricides Closes on $8.625 Million Underwritten Public Offering of Common Stock - ACCESS Newswire
NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND - ACCESS Newswire
Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold... - Proactive Investors UK
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials - Proactive Investors USA
NanoViricides, Inc. Has Filed its Quarterly Report - Chronicle-Tribune
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2024 - Marketscreener.com
NanoViricides Inc. (NNVC) reports earnings - Quartz
NanoViricides: Fiscal Q2 Earnings Snapshot - San Antonio Express-News
NanoViricides: Fiscal Q2 Earnings Snapshot -February 14, 2025 at 04:38 pm EST - Marketscreener.com
Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? - Insider Monkey
7 Best Nanotech Penny Stocks to Invest In - Insider Monkey
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387 - Proactive Investors UK
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape - Oil City Derrick
Powerful New Weapon Against Bird Flu: NanoViricides' Drug Outperforms Tamiflu in Lab Tests - StockTitan
NanoViricides Provides an Update on Its Clinical Program and StrategyNV-387 Could be As Revolutionary as Antibiotics - ACCESS Newswire
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387 - Proactive Investors UK
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NNVC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts - Proactive Investors USA
NanoViricides (NYSE:NNVC) Trading Down 1.8% – What’s Next? - Defense World
NanoViricides to present at MicroCap Conference 2025 in Atlantic City - Proactive Investors Australia
Game-Changing Antiviral Drug Shows 'Superior Results' Against Multiple Viruses$10B Market Potential - StockTitan
Finanzdaten der NanoViricides Inc-Aktie (NNVC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):